The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.
Same compound, route-specific context. Switch forms instead of opening separate pages.
the naturally occurring isomer. The form studied in the published colitis literature. When KPV is referenced without stereochemical notation, L-KPV is implied.
the naturally occurring isomer. The form studied in the published colitis literature. When KPV is referenced without stereochemical notation, L-KPV is implied. stereoiso…
Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.
the naturally occurring isomer. The form studied in the published colitis literature. When KPV is referenced without stereochemical notation, L-KPV is implied.
Human PepT1 expression/mechanistic relevance exists, but no controlled human therapeutic trial of KPV.
KPV is the simplest, safest, and most mechanistically focused compound in this reference — and the one with the clearest gap between what the preclinical science shows and what the clinical evidence confirms. Nothing in the published record creates safety concerns. Everything in the mechanism makes the gut application compelling. And nobody has done the human trial.
The central tension resolved: KPV is derived from alpha-MSH but does not work the way alpha-MSH works in the tissue that matters most for its primary application. In the gut, where melanocortin receptors are not functionally expressed in epithelial cells, KPV bypasses them entirely — entering cells via PepT1, working intracellularly to suppress NF-κB, and accumulating preferentially in inflamed tissue where PepT1 expression is highest. This is a different, more targeted, and more interesting mechanism than the community's 'alpha-MSH without tanning' narrative describes. The oral route is more mechanistically defensible for gut applications than injectable for the same reason — it delivers KPV directly to the transporter in the intestinal epithelium.
The strongest argument for KPV: the preclinical evidence is independently replicated by multiple groups at separate institutions; the mechanism is well-characterized and confirmed by knockout studies; the safety profile has no red flags across any study or dosing range; the oral route makes pharmacological sense in a way that most injectable peptides cannot claim; and the FDA is now reviewing it for the exact indications the science supports. Of all the compounds in the KLOW stack, KPV has the narrowest claim and the cleanest supporting evidence.
The strongest argument for caution: no controlled human trial for any indication. The doses used in animal colitis models do not map cleanly to community practice. The comparison between oral and injectable routes has never been studied in the human gut context. Whether a 500 mcg daily SubQ injection produces gut anti-inflammatory effects comparable to oral dosing in human IBD is not established.
The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.
Adds KPV’s local gut anti-inflammatory signal to the GLOW recovery-and-skin stack.
The Only Human Cathelicidin. Antimicrobial, Anti-Biofilm, Pro-Angiogenic, Immunomodulatory, Wound-Healing. Phase IIb Clinical Evidence in Chronic Wounds. Overexpressed in Rosacea, Ovarian Cancer, Breast Cancer, Lung Cancer, Melanoma. Tumor-Suppressive in Colon and Gastric Cancer. The Most Contextually Bidirectional Compound in this reference. Vitamin D Is Its Most Important Natural Inducer.
Scope appropriateness is the question: local gut peptides are being stacked for barrier integrity and inflammatory signaling, not for systemic regeneration claims.